Occupational Health and Safety (Industrial Hygiene) Experts Clarify Misinformation on PPE, Ventilation, and Disinfection in Relation to COVID-19
April 16, 2020 08:00 ET | AIHA
Falls Church, VA, April 16, 2020 (GLOBE NEWSWIRE) -- As the COVID-19 pandemic spreads across the globe, so does misinformation on personal protective equipment (PPE), decontamination and indoor air...
Apellis logo.jpg
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
June 15, 2019 10:00 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Groundbreaking Legionella Prevention Model Reported
April 16, 2019 10:51 ET | AIHA
Falls Church (VA), April 16, 2019 (GLOBE NEWSWIRE) -- A groundbreaking hazard analysis formula showcased in the April 2019 issue of The Synergist, the magazine of the American Industrial Hygiene...
Apellis logo.jpg
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
February 28, 2019 10:00 ET | Apellis Pharmaceuticals, Inc.
Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide...
Apellis logo.jpg
Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
February 05, 2019 12:02 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
December 03, 2018 13:01 ET | Apellis Pharmaceuticals, Inc.
-  New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) -  CAD patients treated with APL-2 had...
Apellis logo.jpg
Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
December 02, 2018 12:01 ET | Apellis Pharmaceuticals, Inc.
Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of mean hemoglobin to 12.2 g/dL by day 85, an...
Apellis logo.jpg
Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
November 13, 2018 08:00 ET | Apellis Pharmaceuticals, Inc.
- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) - - Cash Position of $220.6 Million at Quarter-End - CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis...
AIHA Releases New Consumer Fact Sheet on Formaldehyde
July 16, 2015 07:08 ET | American Industrial Hygiene Association (AIHA)
FALLS CHURCH, Va., July 16, 2015 (GLOBE NEWSWIRE) -- The American Industrial Hygiene Association® (AIHA) announces the release of a new educational document focused on formaldehyde, specifically...